Immutep Limited American Depositary Shares - IMMP STOCK NEWS

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the successful completion of a 2,000L manufacturing run for its lead product candidate, eftilagimod alpha (efti), in partnership with WuXi Biologics. This achievement ensures readiness for late-stage clinical trials and potential commercial production. The manufacturing process was scaled up from 200L to 2,000L to meet demand for ongoing and future trials. Efti, a first-in-class soluble LAG-3 protein, is being developed for various cancer indications and has received Fast Track Designation from the FDA.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the successful establishment of a GMP compliant manufacturing process for its autoimmune disease candidate, IMP761. Developed by Northway Biotech, this 200L scale production will facilitate IND-enabling studies in the first half of 2023 and subsequent clinical trials. IMP761 is projected to be a groundbreaking treatment by targeting self-reactive T cells in autoimmune diseases. Pre-clinical studies have shown significant reductions in cytokine levels, marking promising advancements in immunotherapy.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced that CEO Marc Voigt will present at The JMP Securities Hematology and Oncology Summit on December 7, 2022, at 11:20 am EST. The event is virtual, offering one-on-one meetings with Mr. Voigt. A live webcast of the presentation will be accessible via their website and archived for later viewing. Immutep focuses on developing LAG-3 immunotherapies for cancer and autoimmune diseases, with lead candidate eftilagimod alpha being tested in various clinical trials.

Immutep Limited (NASDAQ: IMMP) announces a new collaboration with Merck KGaA and Pfizer for the Phase I clinical study INSIGHT-005, focusing on metastatic urothelial cancer. This study builds on positive results from previous trials with eftilagimod alpha (efti) and avelumab, targeting patients who have limited treatment options. The first patient is anticipated to be enrolled in H1 2023. Urothelial cancer is prevalent in the US, with an estimated 81,180 new cases in 2022. This collaboration intends to enhance the potential of efti in various cancer types and improve patient outcomes.

Immutep (ASX: IMM; NASDAQ: IMMP) announced it has secured a cash rebate of A$986,286 (~US$659,303) from the Australian Federal Government's R&D tax incentive program for eligible R&D activities in the 2021 fiscal year, particularly for its TACTI-002 clinical study involving eftilagimod alpha (efti). This follows a previous EU tax incentive of €1,804,341 (~US$1,862,143). The funds will support ongoing clinical trials, with cash flow expected to last into the first half of 2024.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has reported encouraging clinical results from its Phase II TACTI-002 trial. The overall response rate (ORR) for the combination therapy of eftilagimod alpha (efti) and KEYTRUDA® in treating first-line non-small cell lung cancer (NSCLC) increased to 40.4%, with notable improvements across all PD-L1 expression groups. Median duration of response was 21.6 months, showing efficacy irrespective of PD-L1 status. The trial, which included 114 patients, demonstrated a favorable safety profile, with only 9.6% discontinuation due to adverse effects.

Immutep Limited (NASDAQ: IMMP) announced promising early results from the INSIGHT-003 trial, evaluating its lead product candidate, eftilagimod alpha (efti), in combination with anti-PD-1 therapy and chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC). The trial reported an Objective Response Rate (ORR) of 72.7% and a Disease Control Rate (DCR) of 90.9%, indicating strong efficacy, particularly among patients with low PD-L1 expression. The combination therapy demonstrated a favorable safety profile with minimal adverse effects.

Immutep Limited has announced the grant of two new patents for cancer treatment in Japan and South Korea. These patents protect combination therapies involving eftilagimod alpha (efti) and various chemotherapy agents, with an expiry date set for December 19, 2034. This follows the earlier grant of related patents across the US, Europe, China, and Australia. CEO Marc Voigt emphasized the importance of these patents in strengthening the company’s intellectual property and supporting the ongoing INSIGHT-003 clinical trial, with initial efficacy data expected at SITC 2022.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced its late-breaking abstract showcasing efficacy results for eftilagimod alpha in combination with pembrolizumab for non-small cell lung cancer (NSCLC) at the SITC 2022 Annual Meeting. Selected from over 1,500 submissions, it will be presented on November 8, 2022. A webcast on November 10, 2022, will discuss the abstract and Company updates. Additional data from the TACTI-002 Phase II trial will also be presented, with implications for ongoing and future cancer therapies.